Comprehensive Guide to Exploitant Status in France for Biopharmaceutical Companies
France offers one of the most dynamic environments for biopharmaceuticals in Europe. As the 2nd largest pharma market in the EU with an expected growth of 5% annually until 2028, establishing a presence in France is a strategic move for biotechs looking to maximize their global reach.
However, entering this highly regulated market requires the biopharmaceutical companies to set up a subsidiary with an Exploitant Status, a designation mandated by the ANSM to ensure compliance with pharmacovigilance, medical information, advertising, quality control, and regulatory reporting.
Why France ?
- Market Size & Potential: By 2027, France is forecasted to reach €43 billion in pharmaceutical sales, with 50% of the market value stemming from patent-protected drugs.
- Strategic Entry Point: France is part of the EU5, which collectively represents 16% of the global market for new medicines launched between 2017 and 2022.
- Early Access Advantages: France’s Early Access Program (EAP) offers a significant opportunity, enabling pre-market authorization revenue and enhancing product visibility. The country has one of Europe’s most supportive regulatory environments for early access.
Process to Obtain Exploitant Status in France:
1. Create a Legal Entity
The first step involves establishing a French subsidiary or entity, which will hold the Exploitant license. This ensures the company is legally recognized within the French jurisdiction and eligible to apply for the Exploitant status.
2. Find a Physical Office Space
Setting up a physical presence in France is a necessary component of the application process and it must comply with a set of specifications. This office will serve as the headquarters for the subsidiary’s operations, including regulatory compliance.
3. Recruit a Responsible Pharmacist (Pharmacien Responsable, PR)
The Responsible Pharmacist is essential for obtaining the Exploitant license. This person is responsible for ensuring compliance with local regulations, managing pharmacovigilance, batch tracking, and overseeing product recalls. A deputy pharmacist may also need to be recruited as operations expand. He is also the main contact for ANSM and French health Authorities.
4. Prepare the Exploitant Dossier
The company must submit a detailed dossier to the French regulatory body (ANSM). This includes all relevant information about the company’s operations, its compliance plans, and its pharmacovigilance and quality systems.
5. File the Dossier with ANSM
After preparing the necessary documentation, the dossier is submitted to the ANSM (Agence nationale de sécurité du médicament et des produits de santé), which is responsible for granting the Exploitant license.
6. Obtain the Exploitant License
Once the dossier is reviewed and approved by the ANSM, the company is granted Exploitant Status. This status allows the local subsidiary to manage a range of activities such as drug distribution, advertising, medical information, and product recalls.
7. Recruit Additional Resources
To fully operationalize the Exploitant structure, the company may need to recruit additional personnel, including a deputy Responsible Pharmacist (PR), and other support staff to ensure ongoing compliance and operational efficiency.
8. Finalize the Quality Management System (QMS)
The Exploitant Quality Management System (QMS) must be established or adapted to ensure alignment with both local and corporate procedures. This system includes standard operating procedures (SOPs) for compliance with pharmacovigilance, batch tracking, and regulatory inspections.
9. Inform ANSM of the Effective Opening
Once the Exploitant status is approved, and all systems are operational, the company must notify the ANSM of its effective start of operations.
Operational Requirements
Once the Exploitant status is obtained, the subsidiary must adhere to strict operational requirements, including:
- Pharmacovigilance Systems: Ensuring that there are systems in place to monitor and report any adverse effects of the pharmaceutical products.
- Quality Assurance: Implementing Good Distribution Practices (GDP) and maintaining batch tracking to ensure product quality and safety.
- Product Recalls: Being prepared to initiate product recalls if necessary, ensuring consumer safety.
- Regulatory Compliance: Meeting ANSM’s ongoing reporting requirements, handling inspections, and managing compliance with advertising and promotional regulations.
Introducing AzurBio’s Smart Solution for Biotechs
At AzurBio, we simplify your market entry into France by offering a turnkey Exploitant solution. Unlike traditional options that require setting up a French subsidiary, our on-the-shelf Exploitant structure is ANSM-approved and available for acquisition to support your commercialization from day one.
One of our biotech clients accelerated their product launch by 12 months using our turnkey Exploitant solution, ensuring compliance and securing early revenue through the EAP, all while avoiding the lengthy and resource-intensive process of setting up a French affiliate too early.
Download our Case Study : Achieving Rapid Market Entry with AzurBio:
